<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antiemetics used for prophylaxis and treatment of postoperative nausea and vomiting&lt;sup&gt;[1-4]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antiemetics used for prophylaxis and treatment of postoperative nausea and vomiting<sup>[1-4]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Antiemetics used for prophylaxis and treatment of postoperative nausea and vomiting<sup>[1-4]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Dose<sup>[1]</sup></td> <td class="subtitle1">Timing</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Adults</td> </tr> <tr> <td class="indent1" colspan="4"><strong>Glucocorticoid</strong></td> </tr> <tr> <td class="indent2">Dexamethasone</td> <td>IV: 4 to 8 mg</td> <td>After induction of anesthesia</td> <td> </td> </tr> <tr> <td class="indent1" colspan="4"><strong>Serotonin (5-HT<sub>3</sub>) receptor antagonists</strong></td> </tr> <tr> <td class="indent2" rowspan="2">Ondansetron</td> <td class="border_bottom_white">IV: 4 mg</td> <td class="border_bottom_white">IV: End of surgery</td> <td rowspan="2"> <p>May prolong QT interval.</p> ODT or oral soluble film may also be useful for PDNV.</td> </tr> <tr> <td>Oral: 8 mg (ODT or film)</td> <td>Oral: 30 to 60 minutes prior to surgery</td> </tr> <tr> <td class="indent2">Granisetron</td> <td>IV: 0.35 to 3 mg</td> <td>End of surgery</td> <td>May prolong QT interval.</td> </tr> <tr> <td class="indent2">Dolasetron<sup>*</sup></td> <td>IV: 12.5 mg</td> <td>End of surgery</td> <td>May prolong QT interval.</td> </tr> <tr> <td class="indent2">Tropisetron<sup>*</sup></td> <td>IV: 2 mg</td> <td>End of surgery</td> <td>May prolong QT interval.</td> </tr> <tr> <td class="indent2">Palonosetron</td> <td>IV: 0.075 mg</td> <td>At induction of anesthesia</td> <td> </td> </tr> <tr> <td class="indent1" colspan="4"><strong>Anticholinergic</strong></td> </tr> <tr> <td class="indent2">Scopolamine</td> <td>Transdermal patch: 1.5 mg</td> <td>Apply several hours (eg, ≥2 hours) before anesthesia</td> <td>Remove 24 hours after surgery.</td> </tr> <tr> <td class="indent1" colspan="4"><strong>Antidopaminergics</strong></td> </tr> <tr> <td class="indent2">Droperidol</td> <td>IV: 0.625 to 1.25 mg</td> <td>At the end of surgery</td> <td>May prolong QT interval; per FDA recommendation, monitor ECG for 2 to 3 hours after administration.</td> </tr> <tr> <td class="indent2">Haloperidol</td> <td>IV, IM, oral: 1 mg</td> <td>At the end of surgery</td> <td>May prolong QT interval.</td> </tr> <tr> <td class="indent2" rowspan="2">Amisulpride</td> <td class="border_bottom_white">IV, prevention: 5 mg</td> <td class="border_bottom_white">Prevention: At induction of anesthesia</td> <td rowspan="2"> <p>Administer over 1 to 2 minutes.</p> May prolong QT interval.</td> </tr> <tr> <td>IV, treatment: 10 mg</td> <td> </td> </tr> <tr> <td class="indent1" colspan="4"><strong>Neurokinin 1 receptor antagonists</strong></td> </tr> <tr> <td class="indent2" rowspan="2">Aprepitant</td> <td class="border_bottom_white">Oral: 40 mg</td> <td rowspan="2">Preoperative</td> <td rowspan="2">May reduce efficacy of hormonal contraceptives.</td> </tr> <tr> <td>IV: 32 mg over 30 seconds</td> </tr> <tr> <td class="indent2">Fosaprepitant</td> <td>IV: 150 mg</td> <td>Preoperative</td> <td>May reduce efficacy of hormonal contraceptives.</td> </tr> <tr> <td class="indent2">Rolapitant</td> <td>Oral: 90 mg</td> <td>Preoperative</td> <td>Long half-life; useful for prevention of PDNV.</td> </tr> <tr> <td class="indent1" colspan="4"><strong>Antihistamines</strong></td> </tr> <tr> <td class="indent2">Dimenhydrinate</td> <td>IV: 1 mg/kg (maximum single dose: 100 mg)</td> <td>Optimal timing not established</td> <td> </td> </tr> <tr> <td class="indent2">Diphenhydramine</td> <td>IV: 1 mg/kg (maximum single dose: 100 mg)</td> <td>Optimal timing not established</td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Children</td> </tr> <tr> <td class="indent1" colspan="4"><strong>Glucocorticoid</strong></td> </tr> <tr> <td class="indent2">Dexamethasone</td> <td>IV: 0.15 to 0.25<sup>[2]</sup> mg/kg (maximum dose: 4 mg)</td> <td>After induction</td> <td> </td> </tr> <tr> <td class="indent1" colspan="4"><strong>Serotonin (5-HT<sub>3</sub>) receptor antagonists</strong></td> </tr> <tr> <td class="indent2" rowspan="2">Ondansetron</td> <td class="border_bottom_white">IV: 0.1 mg/kg (maximum dose: 4 mg)</td> <td class="border_bottom_white">IV: End of surgery</td> <td rowspan="2"> <p>May repeat dose for postoperative vomiting rescue; maximum total perioperative dose: 8 mg.</p> ODT or oral soluble film may also be useful for PDNV<sup>[3]</sup>.</td> </tr> <tr> <td>Oral, children over 5 years of age<sup>[3]</sup>: 4 mg (ODT or film)</td> <td>Oral: 30 to 60 minutes prior to surgery</td> </tr> <tr> <td class="indent2">Granisetron</td> <td>IV: 40 mcg/kg (maximum dose: 0.6 mg)</td> <td>Optimal timing not established</td> <td>QT prolongation has been observed in pediatric patients 2 to 16 years of age.</td> </tr> <tr> <td class="indent2">Dolasetron<sup>*</sup></td> <td>IV: 0.35 mg/kg (maximum dose: 12.5 mg)</td> <td>End of surgery</td> <td> </td> </tr> <tr> <td class="indent1" colspan="4"><strong>Antihistamines</strong></td> </tr> <tr> <td class="indent2">Dimenhydrinate</td> <td>IV: 0.5 mg/kg IV (maximum dose: 25 mg)</td> <td>Optimal timing not established</td> <td> </td> </tr> <tr> <td class="indent2">Diphenhydramine</td> <td>IV: 0.5 mg/kg IV (maximum dose: 25 mg)</td> <td>Optimal timing not established</td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Combination therapy using different classes of drugs is usually more effective than single-drug therapy for PONV prophylaxis in both children and adults. For rescue therapy after anesthesia, treatment should include a drug from a different class than those that have already been administered unless the effect of the first drug has likely worn off or a potentially inadequate dose has been administered. For additional information including administration, precautions, and drug interactions, refer to the relevant clinical topics and Lexicomp drug monographs and <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program included within UpToDate.</div><div class="graphic_footnotes"><p>ECG: electrocardiogram; FDA: United States Food and Drug Administration; IM: intramuscular; IV: intravenous; ODT: orally disintegrating tablet; PDNV: post-discharge nausea and vomiting; PONV: postoperative nausea and vomiting.</p>
* Not available in the United States.</div><div class="graphic_reference">References:
<ol>
<li>Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2020; 131:411-448.</li>
<li>Madan R, Bhatia A, Chakithandy S, et al. Prophylactic dexamethasone for postoperative nausea and vomiting in pediatric strabismus surgery: a dose ranging and safety evaluation study. Anesth Analg 2005; 100:1622.</li>
<li>Davis PJ, Fertal KM, Boretsky KR, et al. The effects of oral ondansetron disintegrating tablets for prevention of at-home emesis in pediatric patients after ear-nose-throat surgery. Anesth Analg 2008; 106:1117.</li>
<li>Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
</ol></div><div id="graphicVersion">Graphic 130338 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
